Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BFLY.WS vs PHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PHG Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

PHG Overall Winner 6-Pillar Tally: BFLY.WS 0 – 6 PHG Matrix Metrics: BFLY.WS 0 – 10 PHG

As of Nov 20, 2026, Koninklijke Philips N.V. (PHG) is the stronger overall head-to-head candidate over Butterfly Network, Inc. Redeemable Warrants, each whole warrant exercisable for one share of (BFLY.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BFLY.WS carries a Unified Composite Score of 33.5/100 (SELL) at $0.01 (N/M Forward P/E, N/A operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin).

  • Defensive Composite Rating Caution: Although PHG compares more favorably head-to-head, both BFLY.WS (33.5/100 SELL) and PHG (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BFLY.WS vs PHG
BFLY.WS NYSE
Butterfly Network, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$0.01
-50.0% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 347% Vol
Unified Composite Score
33.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
PHG NYSE Head-to-Head Winner
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$28.61
-2.19% 1D
Market Cap $28.6B
TTM Revenue $17.8B
Forward P/E 14.0x
Beta / 30D Vol 0.71β · 38% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 15.0 Fund 39.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.0% over 20 days), RSI 51
RSI-14: 51.0 · SMA20: $29.08 · SMA50: $26.59

6-Pillar Scorecard Institutional Category Breakdown (BFLY.WS 0 – 6 PHG)

Columns: Metric · BFLY.WS · PHG
1. Valuation Multiples PHG
Forward P/E N/M 14.0x
Trailing P/E N/M 25.4x
PEG Ratio N/M 0.90x
EV / Revenue N/M 1.9x
2. Growth & Scale PHG
Revenue Growth (YoY) N/A +2.1%
Earnings Growth (YoY) N/A -85.4%
TTM Revenue (USD) N/A $17.8B
Market Cap N/A $28.6B
3. Profitability & Quality PHG
Gross Margin N/A 46.4%
Operating Margin N/A 8.8%
Net Profit Margin N/A 5.4%
Return on Equity (ROE) N/A 8.6%
4. Balance Sheet & Cash Flow PHG
Cash Generation (TTM) N/A $1.82B
Cash Flow Margin N/A 10.3%
Net Cash / Leverage N/A ROE $5.39B Net Debt (0.70x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PHG
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 111.5% (51st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat PHG
OpEx & R&D Intensity N/A 37.6% of Rev ($6.68B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BFLY.WS (0) vs PHG (10)
Institutional Metric BFLY.WS PHG Criterion Row Edge
Market Capitalization
Scale
N/A $28.6B Larger Scale PHG
Trailing P/E Ratio
Valuation
N/M 25.4x Lower Multiple PHG
Forward P/E Ratio
Valuation
N/M 14.0x Lower Multiple PHG
Revenue Growth (YoY)
Growth
N/A +2.1% Higher Growth PHG
Operating Margin (TTM)
Profitability
N/A 8.8% Higher Margin PHG
Net Profit Margin
Profitability
N/A 5.4% Higher Margin PHG
Return on Equity (ROE)
Capital Efficiency
N/A 8.6% Higher ROE PHG
52-Week Range Position
Momentum
0% ($0–$0) 51% ($24–$33) Stronger Trend PHG
Beta / 30D Volatility
Risk Regime
1.95β · 347% Vol 0.71β · 38% Vol Lower Realized Risk PHG
Unified Institutional Score
Composite Signal
33.5 / 100 (SELL) 40.3 / 100 (SELL) Higher Composite PHG
Trailing 12M Revenue (USD)
Operating Scale
N/A $17.8B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.90x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $1.82B ($5.39B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PHG +79.59 pp
BFLY.WS: -69.89% · PHG: +9.7%
3M Horizon PHG +87.89 pp
BFLY.WS: -76.96% · PHG: +10.93%
6M Horizon PHG +87.89 pp
BFLY.WS: -76.96% · PHG: +10.93%
1Y Horizon PHG +87.89 pp
BFLY.WS: -76.96% · PHG: +10.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BFLY.WS vs PHG. Trailing 12-month operating profitability (BFLY.WS N/A vs PHG 8.8%) and valuation multiples (BFLY.WS N/M vs PHG 14.0x Forward P/E) are benchmarked directly in Pillar 4 below.

BFLY.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
PHG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$17.8B
Gross Margin46.4%
Op. Margin8.8%
ROE / Fwd P/E8.6% · 14.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BFLY.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BFLY.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHG SURGE
12d in phase · OBV DISTRIBUTION
Current IV 111.5%
IV Percentile 51st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BFLY.WS Moat Profile Cyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $28.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($6.68B)
90D Engineering Disclosures 0 Published

Investor FAQ BFLY.WS vs PHG Key Questions & Quantitative Answers

As of Nov 20, 2026, Koninklijke Philips N.V. (PHG) is the stronger overall head-to-head candidate over Butterfly Network, Inc. Redeemable Warrants, each whole warrant exercisable for one share of (BFLY.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BFLY.WS carries a Unified Composite Score of 33.5/100 (SELL) at $0.01 (N/M Forward P/E, N/A operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin). Defensive Composite Rating Caution: Although PHG compares more favorably head-to-head, both BFLY.WS (33.5/100 SELL) and PHG (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

PHG leads the Growth & Scale pillar: BFLY.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $17.8B TTM revenue (46.4% gross margin, 8.8% operating margin). On trailing 12-month operating scale, BFLY.WS generates N/A in USD-normalized revenue versus $17.8B for PHG. In operating R&D and SG&A reinvestment, BFLY.WS deploys N/A (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($6.68B) (0 disclosures) for PHG.

PHG screens cheaper on headline valuation multiples. BFLY.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PHG trades at 14.0x Forward P/E, 25.4x Trailing P/E, 0.90x PEG, and 1.9x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BFLY.WS (N/A ROE) versus PHG (8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, BFLY.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.95β · 347% Vol realized risk). By comparison, PHG carries 111.5% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.71β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Butterfly Network, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share (BFLY.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.